Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Syndax’s revumenib meets primary results in AML trial
Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...
Syndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML Patients
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...
Promising Market Potential and Efficacy of Syndax Pharmaceuticals’ Revumenib Justify Buy Rating
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
The Pharma Letter2d
Syndax shares slide despite pivotal trial success
Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...
Morningstar9d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been ...
Nasdaq9d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute ...